natgillin/translations-raw huggingface dataset:
Ensure the EasyMIX adapter is firmly attached to the vial, before removing the outer cover.
Prepričajte se, da je adapter EasyMIX dobro pričvrščen na vialo, preden odstranite zunanji pokrovček.
Ensure there is a seal between your lips and the mouthpiece.
Dobro ga zatesnite z ustnicami.
Ensure you have the correct dose level in the syringe (e.g.
Zagotovite, da je v injekcijski brizgi pravilna raven odmerka (npr.
Ensure your inhaler is empty.
Prepričajte se, da je inhalator prazen.
ensures close clinical monitoring
intenzivne terapije ali v podobni
ensures close clinical monitoring
priporočljivo klinično spremljanje
Ensures that the pen is ready to dose.
Za zagotovitev, da je peresnik pripravljen za odmerjanje.
Ensuring that each patient receives the patient manual, the patient quick guide and the important patient information leaflet for the Medtronic MiniMed implantable insulin pump system and the patient emergency information card
Zagotovitev, da vsak bolnik dobi priročnik za bolnika, hitri vodnik za bolnika in pomembno navodilo za uporabo implantabilnega sistema insulinske črpalke Medtronic MiniMed ter informacijsko izkaznico bolnika za nujne primere.
ensuring that pen and needle work properly removing air bubbles
zagotovi, da injekcijski peresnik in igla delujeta pravilno, odstrani zračne mehurčke.
Ensuring that the syringe plunger rod is still fully pressed down, invert the vial.
Z do konca pritisnjenim batom injekcijske brizge vialo obrnite.
Ensuring that the syringe plunger rod is still fully pressed down, invert the vial.
Z do konca pritisnjenim nosilcem za bat brizge injekcijske brizge vialo obrnite.
Ensuring you use the right type of insulin - Always check the insulin label before each injection to avoid accidentally confusing Ryzodeg with other insulin products.
uporabo pravega insulina; pred injiciranjem vedno preverite nalepko insulina, da po pomoti ne zamenjate zdravila Ryzodeg in drugih insulinskih zdravil.
Entacapone (n=103)
entakapon (n=103)
Entacapone (n=85)
entakapon (n=85)
Entacapone and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Entakapon in pripravke železa je treba jemati s časovnim presledkom vsaj 2–3 ur (glejte poglavje 4.8).
Entacapone and iron preparations should be taken at least 2–3 hours apart (see section 4.8).
Entakapon in pripravke železa je treba jemati s časovnim presledkom vsaj 2-3 ur (glejte poglavje 4.8).
Entacapone blocks an enzyme that is involved in the break down of levodopa in the body called
Entakapon blokira encim, imenovan katehol-O-metiltransferaza (COMT), ki
Entacapone blocks an enzyme that is involved in the breakdown of levodopa in the body called
Entakapon blokira encim, imenovan katehol-O-metiltransferaza (COMT), ki
Entacapone decreases the metabolic loss of levodopa to 3- O-methyldopa (3-OMD) by inhibiting the COMT enzyme.
Entakapon z zaviranjem encima COMT zmanjšuje izgubo levodope zaradi presnavljanja v 3-O-metildopo (3-OMD).
Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson’s disease and caution should therefore be exercised when driving or operating machines (see also section 4.7).
Pri bolnikih s Parkinsonovo boleznijo je entakapon v povezavi z levodopo povezan s somnolenco in epizodami nenadnih napadov spanja, zato je pri upravljanju motornih vozil in strojev potrebna previdnost (glejte tudi poglavje 4.7).
Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson’s disease and caution should therefore be exercised when driving or operating machines (see section 4.7).
Entakapon v kombinaciji z levodopo povezujejo s pojavom zaspanosti in nenadnega spanca pri bolnikih s Parkinsonovo boleznijo, zaradi česar je potrebna previdnost pri vožnji in upravljanju s stroji (glejte poglavje 4.7).
Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations 5-10% more than from standard levodopa/carbidopa preparations.
Entakapon poveča biološko uporabnost levodope v standardnih pripravkih levodope/benserazida za 5–10 % bolj kot v standardnih pripravkih levodope/karbidope.
Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations 5–10% more than from standard levodopa/carbidopa preparations.
Entakapon poveča biološko uporabnost levodope v standardnih pripravkih levodope/benserazida za 5-10 % bolj kot v standardnih pripravkih levodope/karbidope.
Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations slightly (5-10%) more than from standard levodopa/carbidopa preparations.
Entakapon nekoliko bolj (za 5–10 %) poveča biološko uporabnost levodope iz standardnih pripravkov levodope/benserazida kot iz standardnih pripravkov levodope/karbidope.
Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations slightly (5–10%) more than from standard levodopa/carbidopa preparations.
Entakapon nekoliko bolj (za 5-10 %) poveča biološko uporabnost levodope iz standardnih pripravkov levodope/benserazida kot iz standardnih pripravkov levodope/karbidope.
Entacapone is almost completely metabolized prior to excretion via urine (10 to 20%) and bile/faeces (80 to 90%).
Entakapon se skoraj v celoti presnovi, preden se izloči z urinom (10-20 %) in preko žolča/blata (80- 90 %).
Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson’s disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Entakapon je indiciran kot dodatno zdravilo pri zdravljenju z običajnimi pripravki levodope/benserazida ali levodope/karbidope za uporabo pri odraslih bolnikih s Parkinsonovo boleznijo in motoričnimi nihanji ob koncu delovanja odmerka, ki jih ni mogoče stabilizirati z navedenimi kombinacijami.
Entacapone N=75
entakapon n = 75
entacapone orion 200 mg [folding box only]
entacapone orion 200 mg [samo na zložljivi škatli]
Entacapone Orion 200 mg film-coated tablets
Entacapone Orion 200 mg filmsko obložene tablete entakapon
Entacapone Orion 200 mg film-coated tablets are brownish-orange, oval tablets with "COMT" engraved on one side.
Entacapone Orion 200 mg filmsko obložene tablete so rjavkastooranžne, ovalne tablete z vtisnjenim napisom “COMT” na eni strani.
Entacapone Orion has no effect on relieving the symptoms of Parkinson’s disease unless taken with levodopa.
Zdravilo Entacapone Orion ne lajša simptomov Parkinsonove bolezni, če ga bolnik ne vzame skupaj z levodopo.
Entacapone Orion tablets contain entacapone and are used together with levodopa to treat Parkinson’s disease.
Tablete Entacapone Orion vsebujejo entakapon in jih uporabljamo skupaj z levodopo za zdravljenje Parkinsonove bolezni.
Entacapone Orion taken together with levodopa may lower your blood pressure, which may make you feel light-headed or dizzy.
Zdravilo Entacapone Orion, ki ga jemljete skupaj z levodopo, vam lahko zniža krvni tlak, zaradi česar se vam lahko stemni pred očmi ali postanete omotični.
Entacapone showed little or no inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A and CYP2C19) (see section 4.5).
Entakapon je le malo oziroma sploh ni zaviral drugih vrst izoencimov P450 (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A in CYP2C19) (glejte poglavje 4.5).
Entacapone Teva aids levodopa in relieving the symptoms of Parkinson's disease.
Zdravilo Entakapon Teva pomaga levodopi pri lajšanju simptomov Parkinsonove bolezni.
Entacapone Teva is a ‘generic medicine’.
Zdravilo Entacapone Teva je „generično zdravilo“.
Entacapone Teva is used to treat patients with Parkinson’s disease.
Zdravilo Entacapone Teva se uporablja za zdravljenje bolnikov s Parkinsonovo boleznijo.
Entacapone Teva is used together with levodopa (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patient is having ‘fluctuations’ towards the end of the period between two doses of their medication.
Zdravilo Entacapone Teva se uporablja skupaj z levodopo (bodisi s kombinacijo levodope in benserazida ali kombinacijo levodope in karbidope) pri bolnikih z „nihanji“ proti koncu obdobja med dvema odmerkoma običajne kombinacije zdravil.
Entacapone Teva tablets contain entacapone and are used together with levodopa to treat Parkinson’s disease.
Tablete Entakapon Teva vsebujejo entakapon in jih uporabljamo skupaj z levodopo za zdravljenje Parkinsonove bolezni.
Entecavir
dipivoksiladefovirat
Entecavir and Nevirapine Teva may be co-administered without dose adjustments.
Entekavir in zdravilo Nevirapin Teva lahko dajemo sočasno, brez prilagajanja odmerkov.
Entecavir and Viramune may be coadministered without dose adjustments.
Entekavir in zdravilo Viramune lahko dajemo sočasno, brez prilagajanja odmerkov.
Entecavir exposure among lamivudine-experienced subjects receiving once daily doses of entecavir
Pri z lamivudinom predhodno že zdravljenih bolnikih, ki so prejemali entekavir v odmerkih
Enteric-coated microtablets
Enterično obložene mikrotablete
Enteritis Intestinal obstruction
enteritis obstrukcija črevesja
Enterobacteriaceae S  1 mg/l and R > 4 mg/l
Enterobacteriaceae S  1 mg/l in R > 4 mg/l
Enterobacteriaceae: S ≤ 0.5 mg/L and R > 1 mg/L
Enterobacteriaceae: S ≤ 0,5 mg/l in R > 1 mg/l
Enterococci including Enterococcus faecalis and Enterococcus faecium
Enterokoki, vključno z Enterococcus faecalis in Enterococcus faecium
Enterococci “inappropriate target”
Enterokoki „neobčutljivi“
Enterocolitis haemorrhagic Gastrointestinal haemorrhage Pancreatitis acute
hemoragični enterokolitis krvavitev v prebavilih akutni pakreatitis
Enterocolitis may lead to septic complications and may be associated with fatal outcome.
Vnetje črevesa lahko vodi v septične zaplete, ki so lahko povezani s smrtnim izidom.
enterocolitis, including neutropaenic colitis, caecitis*
enterokolitis, vključno z nevtropeničnim kolitisom, vnetjem slepega črevesa
Enthesitis Resolution n (%) ‡
odpravljen entezitis, n (%)
Enthesitis-related arthritis
artritisa, povezanega z entezitisom
Enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the bone.
Artritis, povezan z entezitisom je vnetna bolezen sklepov in mest, kjer se tetive prirastejo na kost.
Entire male pigs from 8 weeks of age onwards should be vaccinated with 2 doses of 2 ml at least 4 weeks apart, with the second dose normally given 4 to 6 weeks prior to slaughter.
Vsi prašiči samci od 8. tedna starosti dalje naj bodo cepljeni z 2 odmerkoma s po 2 ml vsaj 4 tedne narazen, z drugim odmerkom običajno 4 do 6 tednov pred zakolom.
Entire matrix
celotni matriks
Entire patient population
Celotna populacija bolnikov
Entire Trial Weeks 0-78 N (%)
Celotno preskušanje Tedni 0–78 N (%)
Entrainment plus a score ≥3 on this scale, called Non-24 Clinical Response Scale (N24CRS) was required to be classified as a clinical responder.
Za bolnike z odzivom so šteli tisti, pri katerih so zabeležili utirjenje in rezultat ≥ 3 na lestvici, imenovani lestvica za oceno kliničnega odziva bolnikov z ne-24-urnim ciklusom (Non-24 Clinical Response Scale – N24CRS).
Entresto
Zdravilo Entresto
Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Entresto 24 mg/26 mg filmsko obložene tablete so vijoličasto bele ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "LZ" na drugi.
Entresto 24 mg/26 mg film-coated tablets EU/1/15/1058/001
Entresto 24 mg/26 mg filmsko obložene tablete EU/1/15/1058/001
Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 24 mg/26 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171)
Entresto 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side.
Entresto 49 mg/51 mg filmsko obložene tablete so bledo rumene ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "L1" na drugi.
Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 49 mg/51 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171)
Entresto 49 mg/51 mgfilm-coated tablets sacubitril/valsartan
Entresto 49 mg/51 mg filmsko obložene tablete sakubitril/valsartan
Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Entresto 97 mg/103 mg filmsko obložene tablete so svetlo rožnate ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "L11" na drugi.
Entresto 97 mg/103 mg film-coated tablets EU/1/15/1058/005-007
Entresto 97 mg/103 mg filmsko obložene tablete EU/1/15/1058/005-007
Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Entresto 97 mg/103 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171)
Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Zdravilo Entresto vsebuje valsartan, zato se ga ne sme odmerjati sočasno z drugim zdravilom, ki vsebuje zaviralec angiotenzinskih receptorjev (glejte poglavje 4.4).
Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Zdravilo Entresto vsebuje valsartan, zato se ga ne sme odmerjati sočasno z drugim zdravilom, ki vsebuje zaviralec angiotenzinskih receptorjev (glejte poglavji 4.2 in 4.5).
Entresto has a minor influence on the ability to drive and use machines.
Zdravilo Entresto ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Entresto should not be co-administered with an ACE inhibitor or an ARB.
Zdravila Entresto se ne sme odmerjati sočasno z zaviralcem ACE ali zaviralcem receptorjev angiotenzina II.
Entresto tablets are taken twice a day.
Tablete zdravila Entresto se jemljejo dvakrat na dan.
Entresto’s serious side effects in the main study were similar to those of enalapril, which is already authorised for use in heart failure.
Resni neželeni učinki zdravila Entresto v glavni študiji so bili podobni neželenim učinkom enalaprila, ki je že odobren za uporabo pri srčnem popuščanju.
ENTRY INHIBITORS
Fuzijski zaviralci (zaviralci spajanja)
ENTRY INHIBITORS
Fuzijski zaviralci (zaviralci zlitja)
Entyvio 300 mg powder for concentrate for solution for infusion
Entyvio 300 mg prašek za koncentrat za raztopino za infundiranje
Entyvio 300 mg powder for concentrate for solution for infusion in Type 1 glass vial (20 ml) fitted with rubber stopper and aluminium crimp protected by a plastic cap.
Zdravilo Entyvio 300 mg prašek za koncentrat za raztopino za infundiranje je na voljo v 20 ml stekleni viali (steklo tipa 1), zaprti z gumijastim zamaškom, aluminijastim obročkom in plastično zaporko.
Entyvio 300 mg powder for concentrate for solution for infusion Vedolizumab
Entyvio 300 mg prašek za koncentrat za raztopino za infundiranje vedolizumab
Entyvio contains the active substance vedolizumab.
Zdravilna učinkovina zdravila Entyvio je vedolizumab.
Entyvio does not contain preservatives.
Zdravilo Entyvio ne vsebuje konzervansov.
Entyvio is a white to off-white powder for concentrate for solution for infusion provided in a glass vial with a rubber stopper and a plastic cap.
Zdravilo Entyvio je na voljo v obliki belega do sivobelega praška za koncentrat za raztopino za infundiranje v stekleni viali, zaprti z gumijastim zamaškom in plastično zaporko.
Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
Zdravilo Entyvio je indicirano za zdravljenje zmerno do močno aktivne Crohnove bolezni pri odraslih bolnikih, če pri predhodnem ustaljenem zdravljenju ali zdravljenju z zaviralcem tumorje nekrotizirajočega faktorja alfa (TNFα) odziv na zdravljenje ni bil zadosten, je izzvenel ali pa bolniki takšnega zdravljenja niso prenašali.
Entyvio is produced by a method known as ‘recombinant DNA technology’; it is made by cells into which a gene (DNA) has been introduced that makes them able to produce vedolizumab.
Zdravilo Entyvio se pridobiva z metodo, imenovano „tehnologija rekombinantne DNA“: izdelajo ga celice, v katere so vstavili gen (DNA), s pomočjo katerega lahko tvorijo vedolizumab.
Entyvio is to be used during pregnancy only if the benefits clearly outweigh any potential risk to both the mother and foetus.
Zdravilo Entyvio se lahko med nosečnostjo uporablja le, če koristi zdravljenja jasno prevladajo nad kakršnim koli možnem tveganjem tako za mater kot za plod.
Entyvio should be at room temperature (20°C-25°C) when reconstituted.
Zdravilo Entyvio morate rekonstituirati pri sobni temperaturi (20°C-25°C).
Entyvio treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn’s disease (see section 4.4).
Zdravljenje z zdravilom Entyvio mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnostiko in zdravljenjem ulzeroznega kolitisa ali Crohnove bolezni (glejte poglavje 4.4).
Entyvio was also shown to be more effective than placebo at improving symptoms of Crohn’s disease.
Prav tako se je zdravilo Entyvio izkazalo za učinkovitejše od placeba pri izboljšanju simptomov Crohnove bolezni.
Enuresis, renal cyst, pollakiuria, urine colour abnormal
enureza, ledvična cista, polakisurija, nenormalna barva urina
Enurev Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (glycopyrronium bromide)
Enurev Breezhaler 44 mikrogramov prašek za inhaliranje, trde kapsule glikopironij (glikopironijev bromid)
Enurev Breezhaler also reduced dyspnoea at rest measured using the Transitional Dyspnoea Index.
Poleg tega je zdravilo Enurev Breezhaler zmanjšalo dispnejo v mirovanju po oceni z indeksom spreminjanja dispneje v času (angl.
Enurev Breezhaler capsules are only used with the Enurev Breezhaler inhaler and must not be swallowed.
Kapsule zdravila Enurev Breezhaler se uporabljajo samo z inhalatorjem Enurev Breezhaler in se jih ne sme pogoltniti.
Enurev Breezhaler glycopyrronium bromide
Enurev Breezhaler glikopironijev bromid
Enurev Breezhaler is a medicine that contains the active substance glycopyrronium bromide.
Enurev Breezhaler je zdravilo, ki vsebuje zdravilno učinkovino glikopironijev bromid.
Enurev Breezhaler is an anticholinergic bronchodilator.
Zdravilo Enurev Breezhaler je antiholinergični bronhodilatator.
Enurev Breezhaler is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD.
Zdravilo Enurev Breezhaler je inhalacijski dolgodelujoči antagonist muskarinskih receptorjev (antiholinergik), ki je namenjen uporabi pri vzdrževalnem bronhodilatatornem zdravljenju KOPB enkrat na dan.
Enurev Breezhaler is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Zdravilo Enurev Breezhaler se uporablja za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Enurev Breezhaler must not be used in people who are hypersensitive (allergic) to glycopyrronium bromide or any of the other ingredients.
Zdravila Enurev Breezhaler ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) glikopironijev bromid ali katero koli drugo sestavino zdravila.
Enurev Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD: after 12 weeks of treatment, the increase in FEV1 with Enurev Breezhaler was 97 ml more than with placebo in the first study and 108 ml more in the second study.
Zdravilo Enurev Breezhaler je bilo pri izboljšanju delovanja pljuč bolnikov s KOPB učinkovitejše od placeba: po 12 tednih zdravljenja se je FEV1 pri bolnikih, ki so jemali zdravilo Enurev Breezhaler, v prvi študiji povečal za 97 ml bolj kot pri bolnikih, ki so jemali placebo, v drugi študiji pa za 108 ml.
Enurev Breezhaler with food and drink
Zdravilo Enurev Breezhaler skupaj s hrano in pijačo
Envarsus 0.75 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side.
Zdravilo Envarsus 0,75 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "0,75" na eni strani in "TCS" na drugi strani.
Envarsus 0.75 mg prolonged-release tablets Tacrolimus
Envarsus 0,75 mg tablete s podaljšanim sproščanjem takrolimus
Envarsus 1 mg prolonged-release tablets Tacrolimus
Envarsus 1 mg tablete s podaljšanim sproščanjem takrolimus
Envarsus 4 mg prolonged-release tablets Tacrolimus
Envarsus 4 mg tablete s podaljšanim sproščanjem takrolimus
Envarsus contains the active substance tacrolimus presented in a prolonged release formulation.
Zdravilo Envarsus vsebuje zdravilno učinkovino takrolimus v farmacevtski obliki s podaljšanim sproščanjem.
Envarsus is a ‘hybrid medicine’.
Envarsus je „hibridno zdravilo“.
Envarsus is not interchangeable with other existing tacrolimus containing medicines (immediate release or prolonged release) on an equal dose by dose basis.
Zdravilo Envarsus ni zamenljivo z drugimi obstoječimi zdravili, ki vsebujejo takrolimus (takojšnje sproščanje ali podaljšano sproščanje) na osnovi enakega odmerka.
Envarsus is not recommended for use in children below 18 years of age due to the limited data on safety and/or efficacy
Zdravilo Envarsus se ne priporoča za uporabo pri otrocih, starih manj kot 18 let, zaradi pomanjkanja podatkov o varnosti in/ali učinkovitosti.
Envarsus is routinely administered in conjunction with other immunosuppressive agents in the initial post- operative period.
Zdravilo Envarsus se v začetnem pooperacijskem obdobju uporablja rutinsko skupaj z drugimi imunosupresivi.
Envarsus is taken orally once daily, generally on an empty stomach.
Zdravilo Envarsus se jemlje peroralno enkrat na dan, načeloma na prazen želodec.
Envarsus is used to control your body’s immune response, enabling your body to accept the transplanted organ.
Zdravilo Envarsus se uporablja za obvladovanje telesnega imunskega odziva, kar omogoči, da telo sprejme presajeni organ.
Envarsus should be administered in the morning.
Zdravilo Envarsus se daje zjutraj.
Envarsus should generally be taken on an empty stomach to achieve maximal absorption (see section 5.2).
Za dosego največje absorpcije je treba zdravilo Envarsus praviloma jemati na prazen želodec (glejte poglavje 5.2).
Envarsus therapy requires careful monitoring by adequately qualified and equipped personnel.
Zdravljenje z zdravilom Envarsus mora natančno nadzorovati ustrezno usposobljeno in opremljeno osebje.
Envarsus therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.
Zdravljenje z zdravilom Envarsus je treba začeti upoštevaje koncentracijo ciklosporina v krvi in bolnikovo klinično stanje.
Envarsus therapy should commence at a dose of 0.11 – 0.13 mg/kg/day administered once daily in the morning.
Zdravljenje z zdravilom Envarsus je treba začeti z odmerkom 0,11 do 0,13 mg/kg/dan enkrat na dan zjutraj.
Envarsus therapy should commence at a dose of 0.17 mg/kg/day administered once daily in the morning.
Zdravljenje z zdravilom Envarsus je treba začeti z odmerkom 0,17 mg/kg/dan enkrat na dan zjutraj.
Enviage 150 mg film coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side and “NVR” on the other side.
Enviage 150 mg filmsko obložene tablete so bikonveksne okrogle tablete svetlo roza barve, z oznako ‘IL’ na eni strani in ‘NVR’ na drugi.
Enviage 150 mg film-coated tablets
Enviage 150 mg filmsko obložene tablete
Enviage 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one side and “NVR” on the other side.
Enviage 300 mg filmsko obložene tablete so bikonveksne ovalne tablete svetlo rdeče barve, z oznako ‘IU’ na eni strani in ‘NVR’ na drugi.
Enviage 300 mg film-coated tablets
Enviage 300 mg filmsko obložene tablete